1. Metabolically Healthy Patients With Obesity

2. Introduction/Overview

3. Who Are the Patients With MHO?

4. Phenotyping Patients With MHO: Key Clinical Parameters

5. Clinical and Functional Characteristics: MHO vs MUO

6. The Global Epidemic of Obesity

7. Obesity as a Mediator of CVD

8. Patients With MHO: Dueling Data Sets

9. Weight Loss Improves Metabolic Risk Factors in Both Patients With MHO and Patients With MUO

10. Diabetes Prevention Program: Moderate Weight Loss Associated With Reduced Incidence of T2DM

11. Look AHEAD Results: Incidence of Very-High-Risk Chronic Kidney Disease by Treatment Group

12. SCALE Obesity and Prediabetes Trial

13. Orlistat-Induced Weight Loss and Maintenance at 1 Year

14. Weight Loss From Baseline for the Modified-ITT-LOCF Population and the Completer Population: Naltrexone + Bupropion vs Placebo

15. SCALE: Change in Body Weight (%), Liraglutide vs Placebo

16. SCALE Maintenance: Patients Maintaining Run-In Weight Loss or Regaining ≥ 5%

17. Summary and Conclusions

18. Abbreviations

19. Abbreviations (cont)